#388 — Prostate cancer screening: why current PSA guidelines are failing men and how modern tools improve early detection and save lives
Auto-extracted preview. These recommendations were transcribed and classified from the episode audio. Timestamps link to the source; classifications are not yet editorially verified.
What Peter Attia recommended
In transcript order-
In a protocol
Attia strongly recommends regular PSA blood testing for men as a cheap, effective screening tool to catch prostate cancer early.
“regular PSA testing is so important if one of our objectives in life would be to eliminate prostate cancer mortality
DosageRoutine blood draw; interpret longitudinally over time, not as single valueCaveatsSingle values are noisy; daily fluctuation up to 15%, ejaculation can spike 40%Certaintyexplicitstrong endorsement -
In a protocol
Older transrectal biopsy approach carries 5-7% infection risk and misses anterior/apical tumors; should be replaced where possible.
“infection rates from these biopsies ran between 5% and 7%
CaveatsStill widely practicedCertaintyexplicitmild caution -
In a protocol
Track rate of change in PSA over time (18-month windows) rather than relying on single snapshot values to detect concerning trends.
“PSA is most value as a longitudinal trend, not a single snapshot
DosageIf baseline PSA <4: flag rise >0.35 ng/mL/year over 18 months. If baseline >4: flag rise >0.75 ng/mL/year.Certaintyexplicitstrong endorsement -
In a protocol
Use MRI as next step after concerning PSA velocity, before biopsy, to identify suspicious lesions and calculate PSA density.
“the next step would now be an MRI, which serves as a much higher resolution test
DosageMultiparametric (T2, diffusion, dynamic contrast-enhanced) or biparametric (no contrast)CaveatsMultiparametric requires gadolinium contrast and longer scan timeCertaintyexplicitstrong endorsement -
In a protocol
Calculate PSA concentration divided by prostate volume from imaging to detect disproportionate PSA leakage suggestive of malignancy.
“PSA density, which is simply the PSA concentration in the blood divided by the volume of the prostate
DosagePSA divided by prostate volume from MRI or ultrasoundCertaintyexplicitrecommendation -
In a protocol
Contrast-free MRI variant shown non-inferior to multiparametric MRI in PRIME trial; faster, cheaper, more accessible.
“the bi-parametric MRI identified clinically significant cancer in 143 out of 490 men
Dosage15-20 minutes, no gadolinium contrast requiredCertaintyexplicitrecommendation -
In a protocol
Prefer transperineal over transrectal biopsy approach due to near-zero infection rate and better access to anterior/apical prostate.
“not a single patient who underwent the transperineal biopsy in that study developed an infection
DosageEntry through perineum (skin between anus and scrotum), no prophylactic antibiotics neededCaveatsOnly ~37% of US urologists currently perform thisCertaintyexplicitstrong endorsement -
In a protocol
For low-grade (Gleason 3+3) prostate cancers, monitor with serial testing rather than immediate treatment to avoid overtreatment harms.
“active surveillance is basically something we're doing to ensure that treatment will be timely once it is required, but no sooner
DosageMonitor with PSA, MRI, and additional markers like PHI or 4K scoreCertaintyexplicitstrong endorsement -
Finasteride doesn't cause prostate cancer but suppresses PSA ~50%, masking cancer detection; patients and doctors must adjust PSA values upward.
“his PSA value needs to be at a minimum doubled to be interpreted correctly
DosageMultiply PSA by 2x at 1 year, 2.3x after 2-7 years, 2.5x beyond 7 years; expect no rise in PSA after 12 months on drugCaveatsMany GPs unaware; men on finasteride diagnosed with metastatic cancer at >2x rate of non-usersCertaintyexplicitstrong warning